US Pain Management Drugs Market (By Drug Class: NSAIDs, Opioids, Anesthetics, Antidepressants, Anticonvulsants, Others; By Indication: Arthritic Pain, Neuropathic Pain, Chronic Back Pain, Post-Operative Pain, Cancer Pain, Others; By Distribution Channel: Online Pharmacy, Retail Pharmacy, Hospital Pharmacy) - Industry Analysis, Size, Share, Growth, Trends, and Forecast 2024-2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on US Pain Management Drugs Market 

5.1. COVID-19 Landscape: US Pain Management Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. US Pain Management Drugs Market, By Drug Class

8.1. US Pain Management Drugs Market Revenue and Volume, by Drug Class, 2024-2033

8.1.1 NSAIDs

8.1.1.1. Market Revenue and Volume Forecast (2021-2033)

8.1.2. Opioids

8.1.2.1. Market Revenue and Volume Forecast (2021-2033)

8.1.3. Anesthetics

8.1.3.1. Market Revenue and Volume Forecast (2021-2033)

8.1.4. Antidepressants

8.1.4.1. Market Revenue and Volume Forecast (2021-2033)

8.1.5. Anticonvulsants

8.1.5.1. Market Revenue and Volume Forecast (2021-2033)

8.1.6. Others

8.1.6.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 9. US Pain Management Drugs Market, By Indication

9.1. US Pain Management Drugs Market Revenue and Volume, by Indication, 2024-2033

9.1.1. Arthritic Pain

9.1.1.1. Market Revenue and Volume Forecast (2021-2033)

9.1.2. Neuropathic Pain

9.1.2.1. Market Revenue and Volume Forecast (2021-2033)

9.1.3. Chronic Back Pain

9.1.3.1. Market Revenue and Volume Forecast (2021-2033)

9.1.4. Post-Operative Pain

9.1.4.1. Market Revenue and Volume Forecast (2021-2033)

9.1.5. Cancer Pain

9.1.5.1. Market Revenue and Volume Forecast (2021-2033)

9.1.6. Others

9.1.6.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 10. US Pain Management Drugs Market, By Distribution Channel 

10.1. US Pain Management Drugs Market Revenue and Volume, by Distribution Channel, 2024-2033

10.1.1. Online Pharmacy

10.1.1.1. Market Revenue and Volume Forecast (2021-2033)

10.1.2. Retail Pharmacy

10.1.2.1. Market Revenue and Volume Forecast (2021-2033)

10.1.3. Hospital Pharmacy

10.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 11. US Pain Management Drugs Market and Trend Forecast

11.1. U.S.

11.1.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

11.1.2. Market Revenue and Volume Forecast, by Indication (2021-2033)

11.1.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

Chapter 12. Company Profiles

12.1. Teva Pharmaceutical

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Pfizer

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Abbott

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Mallinckrodt Pharmaceuticals

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Endo International

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. GlaxoSmithKline

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. AstraZeneca

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Depomed

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Merck

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Novartis

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

PROCEED TO BUY :

   USD 5400
   USD 3800
   USD 2100
   USD 2100
   USD 6000

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample